Title: Macitentan and morbidity and mortality in pulmonary arterial hypertension
Authors: Pulido, Tomás ×
Adzerikho, Igor
Channick, Richard N
Delcroix, Marion
Galiè, Nazzareno
Ghofrani, Hossein-Ardeschir
Jansa, Pavel
Jing, Zhi-Cheng
Le Brun, Franck-Olivier
Mehta, Sanjay
Mittelholzer, Camilla M
Perchenet, Loïc
Sastry, B K S
Sitbon, Olivier
Souza, Rogério
Torbicki, Adam
Zeng, Xiaofeng
Rubin, Lewis J
Simonneau, Gérald
SERAPHIN Investigators #
Issue Date: Aug-2013
Series Title: New England Journal of Medicine vol:369 issue:9 pages:809-818
Article number: 10.1056/NEJMoa1213917
Abstract: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Pneumology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science